Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | CTSK | P43235 | 6/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSL | P07711 | 3/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498057 | 1.00 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL1161891 | 0.90 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL12873775 | 0.90 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL13410408 | 0.90 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL24130581 | 0.89 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| Hydrochloric Acid SCHEMBL1161839 | 0.89 | CTSK (0.55) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL24130582 | 0.89 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL6198582 | 0.88 | KYNU (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL13369139 | 0.87 | KYNU (0.60) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL13625105 | 0.87 | KYNU (0.60) | KYNUALDH1A1ALOX15CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1371646-B1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2010-05-19 | — | — | EP | disclosed |
| US-7176199-B2 | Aryl-substituted alicyclic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1371646-A1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | ITGB3, ITGB1, ITGAL | KYNU 2693/4885ALDH1A1 309/4885ALOX15 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.